SPONSOR
Nurix Therapeutics, Inc.
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 1
Conditions studied: Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Follicular Lymphoma (FL)Diffuse Large B-cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)
Nurix Therapeutics, Inc. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL).
The trial portfolio spans Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Nurix Therapeutics, Inc.
How many clinical trials has Nurix Therapeutics, Inc. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Nurix Therapeutics, Inc., of which 2 are actively recruiting participants. These trials cover conditions including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Nurix Therapeutics, Inc. research focus on?
Nurix Therapeutics, Inc. clinical trials span Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), and additional conditions. The research pipeline includes Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Nurix Therapeutics, Inc. clinical trial?
To participate in a Nurix Therapeutics, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Nurix Therapeutics, Inc. trials with current recruitment status updated daily.
Clinical Trials by Nurix Therapeutics, Inc.
NCT07221500 Phase 2
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Chronic Lymphocytic Leukemia (CLL)
NCT04830137 Phase 1
Recruiting
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Chronic Lymphocytic Leukemia (CLL)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology